Anvisa approves new dengue vaccine

According to Anvisa, the new vaccine is made up of four different serotypes of the virus that causes the disease, which guarantees broad protection against it. Last year, Brazil recorded more than a thousand deaths from dengue complications in the country.

Last month, the National Technical Commission on Biosafety (CTNBio) approved the safety of the Qdenga vaccine, which was now awaiting approval from Anvisa.

Another vaccine against dengue already approved in the country, Dengvaxia, can only be used by those who have already had the disease.

The Qdenga vaccine was also evaluated by the European health agency (EMA), from which it also received approval. The granting of registration by Anvisa allows the product to be sold in the country, as long as the approved conditions are maintained. The vaccine, however, will continue to be subject to monitoring of adverse events through pharmacovigilance actions under the responsibility of the company itself.

(With Brazil Agency)

Read also

Deforestation reduces rainfall in tropical areas, study reveals

Large-scale deforestation of forest regions, such as the Amazon, the Congo Basin and Southeast Asia, reduces tropical rainfall, according to a study published this Thursday (2) in the magazine “Nature”. In the Amazon, climate change associated with deforestation could lead to a “path of no return” that would bring the forest closer to a savanna state, researchers warn.

What is the Atlantic Forest?

The Atlantic Forest is a biome that covers around 15% of the Brazilian territory, extending along the country's Atlantic coast. This biome is characterized by its great diversity of fauna and flora species, being considered one of the richest in biodiversity in the world. However, the Atlantic Forest is also one of the most threatened biomes on the planet, with less than 10% of its original coverage still preserved.